1. Home
  2. CATO vs NOTV Comparison

CATO vs NOTV Comparison

Compare CATO & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cato Corporation (The)

CATO

Cato Corporation (The)

HOLD

Current Price

$3.20

Market Cap

68.5M

ML Signal

HOLD

Logo Inotiv Inc.

NOTV

Inotiv Inc.

HOLD

Current Price

$0.83

Market Cap

29.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CATO
NOTV
Founded
1946
1974
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.5M
29.9M
IPO Year
N/A
1997

Fundamental Metrics

Financial Performance
Metric
CATO
NOTV
Price
$3.20
$0.83
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
53.9K
1.6M
Earning Date
11-20-2025
12-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$660,062,000.00
$513,024,000.00
Revenue This Year
N/A
$6.26
Revenue Next Year
N/A
$45.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
4.54
52 Week Low
$2.19
$0.66
52 Week High
$4.92
$6.48

Technical Indicators

Market Signals
Indicator
CATO
NOTV
Relative Strength Index (RSI) 37.97 38.71
Support Level $3.28 $0.79
Resistance Level $3.60 $0.95
Average True Range (ATR) 0.18 0.08
MACD 0.00 0.01
Stochastic Oscillator 25.63 33.30

Price Performance

Historical Comparison
CATO
NOTV

About CATO Cato Corporation (The)

The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

Share on Social Networks: